Emergent BioSolutions Inc reports results for the quarter ended June 30 - Earnings Summary
06/08/2025 23:29
Emergent BioSolutions Inc EBS.N reported quarterly adjusted earnings of 16 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.32. The mean expectation of three analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -72 cents to -26 cents per share. Revenue fell 44.7% to $140.90 million from a year ago; analysts expected $146.37 million. Emergent BioSolutions Inc's reported EPS for the quarter was a loss of 22 cents. The company reported a quarterly loss of $12 million. Emergent BioSolutions Inc shares had fallen by 4.4% this quarter and lost 36.2% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 215.3% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy." Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 55.3% above its last closing price of $6.03 This summary was machine generated from LSEG data August 6 at 10:28 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.49 | 0.16 | Beat |
| Mar. 31 2025 | 0.44 | 0.71 | Beat |
| Dec. 31 2024 | -0.49 | 0.05 | Beat |
| Sep. 30 2024 | 0.14 | 1.37 | Beat |